Key result
Peroxynitrite (ONOO−) concentrations accurately differentiated morbidly obese patients with hypertension or metabolic syndrome from those without (AUC 0.9292; p<0.0001).
Why the study?
The study evaluated nitrosative stress in morbidly obese patients with and without metabolic syndrome.
Observational (n=62)
Nitrosative stress markers, particularly peroxynitrite, parallel the progression of metabolic disturbances in morbid obesity and may help predict the development of hypertension and metabolic syndrome.
Hypothesis-generating for ONOO− as biomarker in morbid obesity; prospective validation required before clinical consideration.
In this pathbreaking study, we evaluated nitrosative stress in morbidly obese patients with and without metabolic syndrome. 62 women with class 3 obesity ( BMI>40 kg/m2 ) were divided into three subgroups: obese patients (OB), obese patients with hypertension (OB+HYP), and obese patients with metabolic syndrome (OB+MS). In comparison to the lean patients, OB had increased levels of serum myeloperoxidase (MPO), plasma nitric oxide (NO), S-nitrosothiols, and peroxynitrite (ONOO−), as well as nitrotyrosine, while oxidized glutathione (GSSG) rose only in OB+HYP group. Interestingly, ONOO− was significantly higher in OB+HYP and OB+MS as compared to OB group, while MPO only in OB+MS group. OB+MS had greater nitrotyrosine and S-nitrosothiol values than OB+HYP. Moreover, peroxynitrite could differentiate OB from OB+HYP and OB+MS (AUC 0.9292; p<0.0001 ; 87.5% sensitivity, 90% specificity) as well as between OB and OB+MS group (AUC 0.9125; p<0.0001 ; 81.25% sensitivity, 83.33%). In conclusion, we showed that MPO activity, NO formation, and nitrosative damage to proteins parallel the progression of metabolic disturbances of obesity. Evaluation of ONOO− concentrations may help predict the development of hypertension and metabolic syndrome in patients with morbid obesity; however, longer-term studies are required for larger numbers of patients.
No takes yet. Share an insight, caveat, or question.
Choromańska et al. (2020) conducted an observational in Morbid obesity (n=62). Hypertension and metabolic syndrome vs. Obesity without hypertension or metabolic syndrome, and lean patients was evaluated on Differentiation of obese patients from those with hypertension and metabolic syndrome using peroxynitrite (ONOO−) (AUC 0.9292, p=<0.0001). Peroxynitrite (ONOO−) concentrations accurately differentiated morbidly obese patients with hypertension or metabolic syndrome from those without (AUC 0.9292; p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: